Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

will-board-exit-and-new-coverage-reframe-globus-medical’s-governance-and-growth-narrative-(gmed)?

Will Board Exit and New Coverage Reframe Globus Medical’s Governance and Growth Narrative (GMED)?

Mar 30, 2026

Globus Medical, Inc. recently announced that Director John A. DeFord, PhD, resigned from its Board of Directors with…

Read more
dell-technologies-analyst-ratings-and-price-targets-|-nyse:dell

Dell Technologies Analyst Ratings and Price Targets | NYSE:DELL

Mar 29, 2026

España Italia 대한민국 日本 Français Benzinga Edge Benzinga Research Benzinga Pro Get Benzinga Pro Data & APIs Events…

Read more
couloir-capital-is-pleased-to-announce-that-it-has-updated-its-research-coverage-on-abcourt-mines

Couloir Capital Is Pleased to Announce That It Has Updated Its Research Coverage on Abcourt Mines

Mar 28, 2026

Vancouver, British Columbia–(Newsfile Corp. – March 25, 2026) – Couloir Capital is pleased to announce that it has…

Read more

Daily Stock Ratings | Stock Price Targets

Mar 28, 2026

Daily analyst ratings and price targets for US stocks . See today’s stock ratings by financial analysts around…

Read more
argan-earnings-are-imminent;-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call

Argan Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Mar 28, 2026

Argan, Inc. (NYSE:AGX) will release earnings for its fourth quarter after the closing bell on Thursday, March 26.…

Read more
biotech-price-target-raised-on-strong-fshd-and-dm1-sirna-data

Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data

Mar 28, 2026

Source: Dr. Yun Zhong (3/27/26) Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising…

Read more
jefferies,-johnson-rice-maintain-buy-on-protagonist-therapeutics-(ptgx)-march-2026

Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) March 2026

Mar 28, 2026

We report a dual analyst reaffirmation on Protagonist Therapeutics, Inc. (PTGX): Jefferies and Johnson Rice both maintained Buy…

Read more
evercore-isi-maintains-negative-on-the-progressive-corporation-(pgr)-march-2026

Evercore ISI Maintains Negative on The Progressive Corporation (PGR) March 2026

Mar 28, 2026

Evercore ISI maintained a Negative rating on The Progressive Corporation (PGR) on March 18, 2026, marking a steady…

Read more
canopy-growth-charts-a-fresh-course-amid-leadership-and-analyst-updates

Canopy Growth Charts a Fresh Course Amid Leadership and Analyst Updates

Mar 28, 2026

Canopy Growth gets a ‘Speculative Buy’ rating with a 57% upside target and announces a 2026 leadership transition…

Read more
d.-boral-capital-initiates-heartbeam-stock-coverage-with-buy-rating

D. Boral Capital initiates Heartbeam stock coverage with buy rating

Mar 27, 2026

D. Boral Capital initiates Heartbeam stock coverage with buy rating

Read more
bicara-therapeutics-earnings-are-imminent;-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call

Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Mar 27, 2026

Bicara Therapeutics Inc. (NASDAQ:BCAX) will release earnings for its fourth quarter before the opening bell on Monday, March…

Read more
metlife-inc.-stock:-analyst-outperform-ratings-and-undervaluation-signal-potential-upside-for-invest

MetLife Inc. Stock: Analyst Outperform Ratings and Undervaluation Signal Potential Upside for Invest

Mar 27, 2026

Keefe, Bruyette & Woods reinstated an Outperform rating on MetLife Inc. (NYSE:MET, ISIN: US59156R1086) with an $87 price…

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 83
  6. 84
  7. 85
  8. 86
  9. 87
  10. 88
  11. 89
  12. ...
  13. 464
  14. »

Posts pagination

Newer posts Page 1 … Page 86 … Page 464 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.